• <code id="kgams"><tr id="kgams"></tr></code>
    <abbr id="kgams"></abbr>
  • <abbr id="kgams"></abbr>
    Home
    Who We Are
    What We Do
    Corporate Responsibility
    News
    Careers
    Investors
    Patients and HCPS
    Contact us
    Careers | Investors | Patients and HCPS | Contact us
    Careers Investors Patients and HCPS Contact us
    Home / Company News / Gan & Lee Pharmaceuticals Announces Approval of Insulin Aspart Injection in Bolivia
    Gan & Lee Pharmaceuticals Announces Approval of Insulin Aspart Injection in Bolivia
    Date:2024-01-26

    Beijing, China, January 26, 2024 - Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087. SH) recently announced that its insulin aspart injection has been approved for the treatment of diabetes by the Agencia Estatal de Medicamentos y Tecnologías en Salud (AGEMED) of Bolivia. This is another achievement following the previous approval of Gan & Lee's insulin glargine injection. The approval signifies Gan & Lee as a marketing authorization holder (MAH) for insulin aspart injection in Bolivia, granting the company the official commercial license to sell the product in the country. This milestone also marks the company’s first success in introducing its insulin aspart to the Latin American region.

     

    Bolivia, located in central South America, has a total population of 12.22 million (2022), with a per capita GDP of $3,600.1(2022, international exchange rate). According to the latest data from the International Diabetes Federation (IDF) Atlas, 10th edition (2021), approximately 395,900 people aged 20-79 years were reported to have diabetes in Bolivia in 2021. The average annual diabetes-related expenditure per patient was $898.8. The prevalence of diabetes in the adult population aged 20-79 years in Bolivia was 5.7%.2


    In Bolivia, the primary supplier of insulin aspart injections was the originator, Novo Nordisk. Gan & Lee's insulin aspart product is the first biosimilar insulin aspart approved in the country, which means we have broken the market monopoly and introduced a high-quality, low-cost biosimilar medicine to Bolivia. This move enriches the local diabetes treatment options and provides a cost-effective alternative for people with diabetes in Bolivia.


    Drawing on years of experience in overseas market development and international resources, Gan & Lee continues to strengthen its commercial network in countries along the "Belt and Road". Bolivia is a participant in the "Belt and Road" initiative and is also one of the target countries in Gan & Lee Pharmaceuticals' “going global” strategy. The approval marks a crucial step in Gan & Lee's commitment to its global strategy, providing multiple treatment options for diabetes patients in Bolivia. This move is in line with the company's efforts to contribute to the globalization of healthcare solutions and reflects the broader vision of improving access to healthcare for diabetes patients in the region.


    References:

    1.     The World Bank. (2024). Bolivia. The World Bank. Retrieved January 25, 2024, from https://data.worldbank.org/country/bolivia

    2.     IDF Diabetes Atlas 10th edition 2021. Available

    at: https://diabetesatlas.org/atlas/tenth-edition/

    cost-effeciions and provides an


    About Gan & Lee

    Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin?), fast-acting lispro injection (Prandilin?), fast-acting aspart injection (Rapilin?), mixed protamine zinc lispro injection (25R) (Prandilin?25), aspart 30 injection (Rapilin?30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin?30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine?).

     

    In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.

     


    Copyright ? 2021 Gan & Lee Pharmaceuticals. All Rights Reserved. 京ICP備10213074號-1 | 京公網(wǎng)安備 11011202003900號
    Our websites

    Subscribe

    I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.
    主站蜘蛛池模板: 91制片厂(果冻传媒)原档破解| 亚洲第一区视频| 中国美女一级看片| fc2ppv在线观看| 粉色视频午夜网站入口| 日韩爱爱小视频| 国产女合集六超多超嫩部| 亚洲欧美成人一区二区在线电影| R级无码视频在线观看| 爽天天天天天天天| 成人伊人青草久久综合网破解版 | 试看60边摸边吃奶边做| 欧美性猛交ⅹxxx乱大交禽| 女王厕便器vk| 亚洲黄色免费观看| 99久9在线|免费| 看看黄色一级片| 大地资源视频在线观看| 亚洲欧美日韩天堂一区二区| 67pao强力打造67194在线午夜亚洲 | 成年人视频在线免费播放| 国产性夜夜夜春夜夜爽| 久久国产一区二区三区| 日本视频一区在线观看免费| 波多结衣一区二区三区| 尤物在线观看精品国产福利片| 制服丝袜一区二区三区| 丰满人妻熟妇乱又伦精品| 给我看播放片免费高清| 好吊妞精品视频| 亚洲欧美日韩在线线精品| 巨胸流奶水视频www网站| 日韩在线你懂的| 台湾佬在线观看| 中文字字幕在线精品乱码app| 精品四虎免费观看国产高清午夜| 天堂а√在线中文在线| 亚洲午夜久久久久久尤物| 麻豆一卡2卡三卡4卡网站在线| 最近中文字幕在线mv视频在线 | 国产无遮挡又黄又爽在线视频|